Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Neoadjuvant Therapy. Found 27 abstracts

no pagination
Rouvinov K, Plimack ER, Zibelman M, Ghatalia P, Geynisman DM. Update on perioperative systemic therapy for urothelial carcinoma. Clinical advances in hematology & oncology : H&O. 2019 Mar;17(3):176-83.
Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong YN, Viterbo R, Sonpavde G, Harshman LC, Crabb S, Alva A, Chowdhury S, De Giorgi U, Srinivas S, Agarwal N, Bamias A, Baniel J, Golshayan AR, Ladoire S, Sternberg CN, Cerbone L, Yu EY, Bellmunt J, Vaishampayan U, Niegisch G, Hussain S, Bowles DW, Morales-Barrera R, Milowsky MI, Theodore C, Berthold DR, Sridhar SS, Powles T, Rosenberg JE, Galsky MD. Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. European urology focus. 2018 Dec;4(6):937-45.   PMCID: PMC5626651
Hoffman JP, Reddy SS. Is It Time for Total Neoadjuvant Therapy for Patients With Resectable Pancreatic Adenocarcinoma?. J Oncol Pract. 2016 Sep;12(9):780-1.   PMCID: Letter
Meyer JE, Cohen SJ, Ruth KJ, Sigurdson ER, Hall MJ. Young Age Increases Risk of Lymph Node Positivity in Early-Stage Rectal Cancer. Journal of the National Cancer Institute. 2016 Jan;108(1).   PMCID: PMC4715232
Meyer LA, Cronin AM, Sun CC, Bixel K, Bookman MA, Cristea MC, Griggs JJ, Levenback CF, Burger RA, Mantia-Smaldone G, Matulonis UA, Niland JC, O'Malley DM, Wright AA. Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol. 2016 Sep 06;34(32):3854-63.   PMCID: PMC5477982
Zibelman M, Plimack ER. Systemic therapy for bladder cancer finally comes into a new age. Future Oncol. 2016 Oct;12(19):2227-42.   PMCID: PMC5066115
Burness ML, Obeid EI, Olopade OI. Triple negative breast cancer in BRCA1 mutation carriers with a complete radiologic response to neoadjuvant paclitaxel: a case report. Clin Breast Cancer. 2015 Apr;15(2):e155-8.
Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE, Retrospective International Study of Cancers of the Urothelial Tract I. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015 Aug;121(15):2586-93.
Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, Golemis EA, Ross EA. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol. 2015 Dec;68(6):959-67.   PMCID: PMC4764095
Telli ML, Jensen KC, Vinayak S, Kurian AW, Lipson JA, Flaherty PJ, Timms K, Abkevich V, Schackmann EA, Wapnir IL, Carlson RW, Chang PJ, Sparano JA, Head B, Goldstein LJ, Haley B, Dakhil SR, Reid JE, Hartman AR, Manola J, Ford JM. Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. J Clin Oncol. 2015 Apr 06;33(17):1895-901.   PMCID: 4451172
Wang LS, Shaikh T, Handorf EA, Hoffman JP, Cohen SJ, Meyer JE. Dose escalation with a vessel boost in pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Practical radiation oncology. 2015 Sep;5(5):e457-63.   PMCID: 4814166
Wong SJ, Moughan J, Meropol NJ, Anne PR, Kachnic LA, Rashid A, Watson JC, Mitchell EP, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG. Efficacy Endpoints of Radiation Therapy Group Protocol 0247: A Randomized, Phase 2 Study of Neoadjuvant Radiation Therapy Plus Concurrent Capecitabine and Irinotecan or Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer. International Journal of Radiation Oncology Biology Physics. 2015 Jan;91(1):116-23.   PMCID: 4385459
Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, Chen DY, Lallas CD, Wong YN, Lin J, Kutikov A, Dotan E, Brennan TA, Palma N, Dulaimi E, Mehrazin R, Boorjian SA, Kelly WK, Uzzo RG, Hudes GR. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014 Jun 20;32(18):1895-901.   PMCID: PMC4050203
Plimack ER, Hoffman-Censits J, Rosenberg JE, Wong YN, Bellmunt J, Choueiri TK. Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye [Letter]. J Clin Oncol. 2014 Dec 20;32(36):4171-2.
Tomaszewski JJ, Handorf E, Corcoran AT, Wong YN, Mehrazin R, Bekelman JE, Canter D, Kutikov A, Chen DY, Uzzo RG, Smaldone MC. Care transitions between hospitals are associated with treatment delay for patients with muscle invasive bladder cancer. J Urol. 2014 Nov;192(5):1349-54.   PMCID: PMC4422495
Willis DL, Flaig TW, Hansel DE, Milowsky MI, Grubb RL, Al-Ahmadie HA, Plimack ER, Koppie TM, McConkey DJ, Dinney CP, Hoffman VA, Droller MJ, Messing E, Kamat AM. Micropapillary bladder cancer: current treatment patterns and review of the literature. Urol Oncol. 2014 Aug;32(6):826-32.   PMCID: PMC4687398
Konski A, Li T, Sigurdson E, Cohen SJ, Small W, Spies S, Yu JQ, Wahl A, Stryker S, Meropol NJ. Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation. Int J Radiat Oncol Biol Phys. 2009 May;74(1):55-9.   PMCID: PMC2933375
von Mehren M, Watson JC. Perioperative tyrosine kinase inhibitors for GIST: standard ... or an idea that needs further investigation?. Oncology (Williston Park). 2009 Jan;23(1):65-6.   PMCID: PMC 2861343
Langer CJ. Resectable non-small cell lung cancer in the elderly: is there a role for adjuvant treatment?. Drugs Aging. 2008 Jan;25(3):209-18.
Stitzenberg KB, Watson JC, Roberts A, Kagan SA, Cohen SJ, Konski AA, Hoffman JP. Survival after pancreatectomy with major arterial resection and reconstruction. Ann Surg Oncol. 2008 May;15(5):1399-406.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Neoadjuvant Therapy

Neoadjuvant Therapy Female therapeutic use Aged pathology methods Male Middle Aged drug therapy Urinary Bladder Neoplasms Adult surgery Antineoplastic Combined Chemotherapy Protocols Neoplasm Invasiveness Adjuvant Chemotherapy Antineoplastic Agents Prognosis 80 and over Aged administration & dosage Transitional Cell Carcinoma therapy Neoplasm Staging Cystectomy Cisplatin mortality genetics Adenocarcinoma Retrospective Studies Deoxycytidine Treatment Outcome Drug Administration Schedule analogs & derivatives Rectal Neoplasms Doxorubicin Survival Rate Pancreatic Neoplasms Methotrexate Lymph Node Excision statistics & numerical data Fluorouracil Granulocyte Colony-Stimulating Factor Neoplasm Metastasis Combined Modality Therapy Logistic Models Disease-Free Survival metabolism Chemoradiotherapy Mutation Triple Negative Breast Neoplasms analysis radiotherapy Gene Expression Profiling Age Factors Proportional Hazards Models Protective Agents chemistry Carboplatin Prospective Studies Survival Analysis dosage Vinblastine Urothelial carcinoma bladder cancer Young Adult Bladder cancer Randomized Controlled Trials as Topic Smooth Muscle Lymph Nodes DNA Repair quality indicators Filgrastim Dose Fractionation Carcinoma Nonparametric Statistics Non-Small-Cell Lung Carcinoma SEER Program Clinical Trials as Topic Pancreatectomy Piperazines Capecitabine Positron-Emission Tomography Salvage Therapy Pd-1 Tumor Biomarkers Follow-Up Studies Pyrroles Muscle Neoplasms Urothelium Hospitals Paclitaxel gemcitabine plus cisplatin Robot-assisted surgery drug effects Benzamides Analysis of Variance doxorubicin Radiotherapy Dosage Micropapillary disclosed No writing assistance was utilized in the production of this Radiotherapy urothelial carcinoma The authors have no other relevant affiliations or financial involvement with any Survey Atm institutionally directed clinical trial support from Horizon Pharma ER Plimack Gastrointestinal Stromal Tumors Perioperative Care Adolescent Recombinant Proteins Reconstructive Surgical Procedures Fancc neoadjuvant Muscle-invasive disease United States Protein Kinase Inhibitors Margins of Excision Fluorodeoxyglucose F18 Cytoreduction Surgical Procedures Genomic Instability administration & Eli Lilly has served on advisory boards and as consultant for Genentech BRCA1 Genes Biomarkers diagnosis analogs & Celiac Artery chemically induced Heterozygote BRCA2 Protein Cisplatin resistance Risk Factors Immunotherapy vinblastine pharmacokinetics methotrexate Pancreaticoduodenectomy Mitomycin Biological Tumor Markers secondary radionuclide imaging Lymphatic Metastasis Neoadjuvant chemotherapy urinary bladder neoplasms cisplatin Phase II Clinical Trials as Topic Radiation-Sensitizing Agents Multicenter Studies as Topic Medical Oncology Radiopharmaceuticals Adjuvant Radiotherapy
Last updated on Friday, December 06, 2019